Merck & Co., Inc. (MRK) Stock Forecast, Price & News

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

Is Merck & Co., Inc. a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 7 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc. or view top-rated stocks.

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 21,570,000 shares, an increase of 27.0% from the April 30th total of 16,980,000 shares. Based on an average trading volume of 11,500,000 shares, the short-interest ratio is presently 1.9 days.
View Merck & Co., Inc.'s Short Interest.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Merck & Co., Inc..

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings data on Thursday, April, 28th. The company reported $2.14 EPS for the quarter, beating the consensus estimate of $1.83 by $0.31. The company had revenue of $15.90 billion for the quarter, compared to analysts' expectations of $14.64 billion. Merck & Co., Inc. had a net margin of 26.27% and a trailing twelve-month return on equity of 47.86%. The firm's quarterly revenue was up 31.6% on a year-over-year basis. During the same quarter last year, the company posted $1.40 EPS.
View Merck & Co., Inc.'s earnings history.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, May 24th. Shareholders of record on Wednesday, June 15th will be given a dividend of $0.69 per share on Friday, July 8th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date is Tuesday, June 14th.
View Merck & Co., Inc.'s dividend history.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. pays an annual dividend of $2.76 per share and currently has a dividend yield of 2.99%. Merck & Co., Inc. has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Merck & Co., Inc. is 49.37%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 38.28% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $7.24-$7.36 for the period, compared to the consensus earnings per share estimate of $7.24. The company issued revenue guidance of $56.90 billion-$58.10 billion, compared to the consensus revenue estimate of $57.35 billion.

What price target have analysts set for MRK?

15 brokerages have issued 12-month target prices for Merck & Co., Inc.'s stock. Their forecasts range from $70.00 to $110.00. On average, they expect Merck & Co., Inc.'s share price to reach $91.27 in the next twelve months. This suggests that the stock has a possible downside of 1.9%.
View analysts' price targets for Merck & Co., Inc. or view top-rated stocks among Wall Street analysts.

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:

• Mr. Kenneth C. Frazier, Exec. Chairman (Age 67, Pay $4.58M) (LinkedIn Profile)
• Mr. Robert M. Davis J.D., Pres, CEO & Director (Age 55, Pay $4.4M) (LinkedIn Profile)
• Ms. Caroline Litchfield, Exec. VP & CFO (Age 53, Pay $2.05M) (LinkedIn Profile)
• Mr. Richard R. DeLuca Jr., Exec. VP & Pres of Merck Animal Health (Age 59, Pay $2.05M) (LinkedIn Profile)
• Dr. Dean Y. Li M.D., Ph.D., Exec. VP & Pres of Merck Research Laboratories (Age 60, Pay $2.4M)
• Mr. David Michael Williams, Exec. VP and Chief Information & Digital Officer (Age 53)
• Mr. Peter Dannenbaum, VP of Investor Relations
• Ms. Jennifer L. Zachary, Exec. VP & Gen. Counsel (Age 44)
• Lisa LeCointe-Cephas, Sr. VP and Chief Ethics & Compliance Officer (Age 40)
• Ms. Jennifer Mauer, VP of Global Communications

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Merck & Co., Inc.'s key competitors?

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of MRK's competitors.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.55%), BlackRock Inc. (8.07%), State Street Corp (4.68%), Wellington Management Group LLP (1.81%), Bank of New York Mellon Corp (1.30%) and Charles Schwab Investment Management Inc. (1.19%). Company insiders that own Merck & Co., Inc. stock include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis and Sanat Chattopadhyay.
View institutional ownership trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Wellington Management Group LLP, Bank of Nova Scotia, Toronto Dominion Bank, First Trust Advisors LP, Dimensional Fund Advisors LP, Robeco Institutional Asset Management B.V., and Bahl & Gaynor Inc.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Caroline Litchfield, Frank Clyburn, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc. or view top insider-selling stocks.

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc., Caisse DE Depot ET Placement DU Quebec, Bank of New York Mellon Corp, Arrowstreet Capital Limited Partnership, Swiss National Bank, and Capital Wealth Planning LLC.
View insider buying and selling activity for Merck & Co., Inc. or or view top insider-buying stocks.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $93.08.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. has a market capitalization of $235.38 billion and generates $48.70 billion in revenue each year. The company earns $13.05 billion in net income (profit) each year or $5.59 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

Merck & Co., Inc. employs 68,000 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at (908) 740-4000, via email at [email protected], or via fax at 908-735-1253.